MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) is a selective, CNS penetrant, and orally active p38α MAPK inhibitor with a Ki of 101 nM. MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia [1].

MW-150 dihydrochloride dihydrate concentration-dependently inhibits the ability of the endogenous p38αMAPK to phosphorylate an endogenous substrate MK2 in activated glia [1]. MW-150 dihydrochloride dihydrate blocks in a concentration-dependent manner the increased IL-1β production by activated glia. The IC 50 values are 332 nM and 936 nM for MK2 and IL-1β, respectively [1].

MW-150 dihydrochloride dihydrate (2.5 mg/kg; oral daily for 3 4 months) improves the performance of APP/PS1 transgenic (Tg) mice in radial arm water maze (RAWM) and contextual fear conditioning tests [1]. MW-150 dihydrochloride dihydrate (2.5 mg/kg; given i.p.; daily for 14 days) treatment in APP NLh/NLh × PS P264L/P264L knock-in mouse (with no overexpression of the amyloid precursor protein) exhibits RAWM behavior indistinguishable from WT mice [1].